Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca

Last Updated: January 29, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,357,476

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,357,476
Title:Method for treating coronary artery disease
Abstract: The use of a combination of carvedilol, metformin, evolocumab, and one or more statins to remove atheromas from coronary arteries and thereby treat coronary artery disease is disclosed. The method treats coronary artery disease by removing one or more atheromas from one or more coronary arteries of a patient by administering a therapeutically effective amount of: (a) carvedilol; (b) metformin; (c) evolocumab; and (d) one or more statins; or a pharmaceutically acceptable salt, prodrug, or derivative of one or more of (a)-(d). In some embodiments, the one or more statins comprise simvastatin. In some embodiments, the one or more statins comprise rosuvastatin. In some embodiments, the one or more statins comprise atorvastatin. In some embodiments, the one or more statins comprise pravastatin.
Inventor(s): Ahmad; Anis (Rock Island, IL)
Assignee:
Application Number:16/186,495
Patent Claims:1. A method of treating coronary artery disease by removing one or more atheromas from one or more coronary arteries of a patient comprising administering a therapeutically effective amount of: a. carvedilol; b. metformin; c. evolocumab; and d. one or more statins.

2. The method of claim 1, wherein the one or more statins comprise simvastatin.

3. The method of claim 1, wherein the one or more statins comprise rosuvastatin.

4. A method of treating coronary artery disease by removing one or more atheromas from one or more coronary arteries of a patient comprising administering a therapeutically effective amount of: a. carvedilol; b. metformin; c. evolocumab; and d. atorvastatin.

5. The method of claim 1, wherein the one or more statins comprise pravastatin.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Baxter
Harvard Business School
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.